The company stops its Phase 2 study of nivisnebart after early data suggest it is unlikely to slow disease.
California-based biotech Alector has pulled the plug on its Phase 2 PROGRESS-AD trial of nivisnebart (AL101/GSK4527226), a once-promising therapy for early Alzheimer’s disease, after an independent data monitoring committee concluded the study was unlikely to meet its main goal: slowing cognitive decline.
“This outcome is disappointing for patients and families affected by Alzheimer’s disease and underscores the complexity of developing effective treatments for this devastating disease,” said Dr Arnon Rosenthal, CEO of Alector [1].
Rosenthal expressed profound gratitude to the patients, caregivers, investigators and staff involved in the PROGRESS-AD trial, noting that their participation was instrumental in advancing the scientific community’s understanding of progranulin biology in neurodegeneration.
The CEO further affirmed the company’s ongoing commitment to advancing its extensive portfolio of neurodegenerative disease treatments, which includes several proprietary candidates developed through its ABC platform.
It’s the kind of statement that carries both weight and restraint. Acknowledging loss, but also pointing forward.
“Futility analysis” is one of those clinical terms that sounds harsher than it is. It doesn’t mean the drug did nothing. It means that, based on the data so far, it’s highly unlikely to deliver the kind of meaningful benefit the trial was designed to prove.
Think of it like running a marathon and realizing halfway through that your pace won’t get you to the finish line on time. You could keep going, but at a cost. In clinical trials, the cost includes years of work, millions in funding and the continued participation of patients who might otherwise enroll in more promising studies. So trials stop, not out of failure, but out of prioritization.
Nivisnebart wasn’t chasing the most crowded target in Alzheimer’s research. Instead of going directly after amyloid plaques, it focused on boosting progranulin, a protein that helps regulate inflammation and supports the health of brain cells.
In theory, it’s a compelling angle. Alzheimer’s isn’t just about toxic buildup; it’s also about the brain’s environment breaking down, or its ability to clean up waste, manage inflammation and keep neurons alive. Progranulin sits right in the middle of that ecosystem. But biology, especially in the brain, rarely responds to a single intervention.
The discontinuation of PROGRESS-AD doesn’t necessarily invalidate the approach. It does, however, reinforce a growing realization in the field: Alzheimer’s may require a combination approach – multiple levers pulled at once rather than a single “silver bullet.”
In longevity science, we often talk about breakthroughs as if they arrive fully formed. In reality, they’re built on layers of partial answers, wrong turns and recalibrations. This is one of those moments.
Every halted trial still produces data about what works, what doesn’t and where the biology resists intervention. In diseases like Alzheimer’s, that kind of information is essential. It also forces companies to sharpen their strategy.
Alector isn’t stepping away from neurodegeneration. If anything, it’s leaning in with a broader, more diversified pipeline and a technology platform designed to solve one of the field’s most persistent problems: getting drugs into the brain.
The company’s Alector Brain Carrier (ABC) platform is built to help therapies cross the blood-brain barrier more effectively. If the brain is a locked room, ABC is an attempt to build a better key, one that allows treatments to enter at meaningful levels without invasive delivery methods.
Using this platform, Alector is advancing several programs:
- An anti-amyloid beta antibody (AL037/AL137), targeting entry into clinical trials by early 2027
- A tau-targeting siRNA therapy for Alzheimer’s and related conditions
- Additional siRNA programs aimed at proteins linked to Parkinson’s disease and inflammation
- An enzyme replacement therapy for Parkinson’s disease, also moving toward a 2027 milestone
Taken together, the pipeline reflects a shift from single bets to layered strategies – targeting toxic proteins, restoring missing functions and modulating the immune system in the brain.
The timing of this announcement matters. Alzheimer’s research is in a transitional phase: recent approvals of amyloid-targeting drugs have brought cautious optimism, but also exposed their limitations. Modest benefits, safety concerns and ongoing debate about real-world impact.
Against that backdrop, the end of PROGRESS-AD feels less like an isolated setback and more like part of a broader recalibration. The field is expanding its lens, from plaques alone to the full complexity of neurodegeneration. That includes inflammation, genetics, protein clearance and even systemic factors like metabolism. It’s messier science, but it may also be more honest.
For those following the longevity space, Alzheimer’s is a defining challenge. Living longer only matters if cognitive health keeps pace. Without it, added years risk becoming years of dependence, memory loss and disconnection from self. That’s why moments like this deserve attention because they show how the system learns.
Alector’s halted trial is part of a larger narrative: one in which extending lifespan and preserving brain health are deeply intertwined, and where progress often comes disguised as a pivot.
Alector and its partner, GSK, plan to share the full results from the PROGRESS-AD trial at a future medical meeting. In the meantime, the company is redirecting its energy toward programs it believes can deliver more meaningful outcomes.
